반응식
Cl[CH2:2][C:3]1[O:7][C:6]([C:8]2[CH:13]=[CH:12][C:11]([C:14]3[C:19]([CH3:20])=[CH:18][CH:17]=[C:16]([C:21]([NH:23][CH:24]4[CH2:26][CH2:25]4)=[O:22])[CH:15]=3)=[CH:10][CH:9]=2)=[N:5][N:4]=1.[I-].[K+].CN(C=O)C.[NH:34]1[CH2:39][CH2:38][S:37][CH2:36][CH2:35]1>>[CH:24]1([NH:23][C:21]([C:16]2[CH:15]=[C:14]([C:11]3[CH:12]=[CH:13][C:8]([C:6]4[O:7][C:3]([CH2:2][N:34]5[CH2:39][CH2:38][S:37][CH2:36][CH2:35]5)=[N:4][N:5]=4)=[CH:9][CH:10]=3)[C:19]([CH3:20])=[CH:18][CH:17]=2)=[O:22])[CH2:26][CH2:25]1참가 물질
5
반응물 4
생성물 1
실험 절차
4′-[5-(Chloromethyl)-1,3,4-oxadiazol-2-yl]-N-cyclopropyl-6-methyl-1,1′-biphenyl-3-carboxamide (Intermediate 45) (37 mg) and potassium iodide (5 mg) were mixed in thiomorpholine (2 ml) and DMF (2 ml) and the reaction stirred at room temperature for 18 hours. The solvents were evaporated under vacuum and the residue purified by bond-elut (silica), eluting with an ethyl acetate/cyclohexane gradient. After evaporation of the solvent this gave N-cyclopropyl-6-methyl-4′-[5-(thiomorpholin-4-ylmethyl)-1,3,4-oxadiazol-2-yl]-1,1′-biphenyl-3-carboxamide.
후처리
- customThe solvents were evaporated under vacuum
- customthe residue purified by bond-elut (silica)
- washeluting with an ethyl acetate/cyclohexane gradient
- customAfter evaporation of the solvent this gave N-cyclopropyl-6-methyl-4′-[5-(thiomorpholin-4-ylmethyl)-1,3,4-oxadiazol-2-yl]-1,1′-biphenyl-3-carboxamide
출처 및 근거
- ORD 기록
- ord-0408fa70f4a3405f9db5e9fa86ea2549
- 출처 데이터셋
- uspto-grants-2008_09
- 특허 번호
- US07425555B2
연결된 노트
불러오는 중…